WeVote
Log In

Bill

Bill

HF 2009

A bill for an act relating to manufacturers and distributors of 340B drugs.

2025-2026 Regular Session Introduced by Brett Barker

Iowa bill HF 2009 regulates 340B pharmaceutical program manufacturers and distributors to address drug pricing and access for eligible healthcare providers.

Subcommittee recommends passage.
#distributors #drugs #insurance #manufacturing
0
WeVote Research Nonpartisan
Bill Summary · HF 2009

Legislative bill overview

HF 2009 addresses the regulation of manufacturers and distributors participating in the 340B drug pricing program, a federal initiative that requires pharmaceutical manufacturers to provide significant discounts on medications to eligible healthcare entities. The bill, introduced by Rep. Brett Barker, has advanced through subcommittee review with a recommendation for passage as of January 21, 2026.

Why is this important

The 340B program affects drug pricing for hospitals, clinics, and other healthcare providers serving vulnerable populations, potentially influencing medication costs and access. Changes to how manufacturers and distributors operate within this program could impact drug availability, pricing structures, and the financial sustainability of healthcare organizations that rely on these discounts.

Potential points of contention

  • Manufacturer compliance costs: Stricter regulations on manufacturers could increase administrative burdens and potentially lead to higher baseline drug prices or reduced participation
  • Distributor market dynamics: Rules governing distributor practices might affect competition, supply chain efficiency, and smaller healthcare entities' ability to access discounted drugs
  • Program integrity vs. access: Balancing fraud prevention and program oversight against ensuring eligible entities can actually utilize 340B discounts effectively

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.